FDA Approved: Isemblyd (apitegromab) is the first muscle-targeted therapy approved for spinal muscular atrophy, for patients aged two and older on SMN2 standard-of-care treatment.
Evidence: Approval was based on Phase III SAPPHIRE (NCT05156320), which showed statistically significant motor function gains at one year when Isemblyd was added to SMN2 therapy.
Access: Scholar Rock has launched a patient-support program, is working with payers, and expects to ship the drug "in the coming days," with administration possible at home or in infusion centers.
FDA Approves Isemblyd (apitegromab): First Muscle-Targeted Therapy for Spinal Muscular Atrophy
Scholar Rock says Isemblyd will be available to ship in "the coming days". Credit: Panchenko Vladimir / Shutterstock.com.
The U.S. Food and Drug Administration has approved Isemblyd (apitegromab), Scholar Rock's selective myostatin inhibitor, marking the first muscle-targeted treatment to reach the market for spinal muscular atrophy (SMA).
What Isemblyd Does
Isemblyd is indicated for patients aged two years and older with SMA who are already receiving a standard-of-care (SoC) therapy directed at the survival motor neuron 2 (SMN2) gene. Unlike SMN2-directed treatments that boost a neuron-protecting protein, Isemblyd targets muscle by blocking the conversion of the protein myostatin into its active form—thereby reducing a natural brake on skeletal muscle growth and improving muscle function.
Clinical Evidence
The FDA's decision was based on the Phase III SAPPHIRE study (NCT05156320), in which Isemblyd given in combination with SMN2-directed therapy produced a statistically significant improvement in motor function and physical abilities at one year compared with SMN2 therapy alone.
Regulatory Backstory
Last year the FDA initially declined approval after a routine inspection found observations at a third-party Catalent fill-finish facility used to manufacture Isemblyd. Regulators clarified those inspection observations were related to the manufacturing site and not to the drug's safety or efficacy. Following remediation and review, the agency has now approved the product.
Access, Administration, and Support
Scholar Rock has launched a patient-support program to help eligible individuals access Isemblyd. The program offers personalized assistance with insurance navigation and financial support, education about SMA and its treatments, and guidance on site-of-care options. Scholar Rock says Isemblyd will be ready to ship "in the coming days" and that the treatment can be administered either at home or in infusion centers.
Market Outlook
According to a recent GlobalData report (parent company of Pharmaceutical Technology), the arrival of three myostatin inhibitors, including Isemblyd, is expected to drive future growth in the SMA market. Analysts project this drug class could contribute about $253 million of an estimated $3 billion in total indication sales by 2033.
Bottom line: Isemblyd offers a complementary, muscle-directed approach to SMA care for patients already receiving SMN2 therapies, backed by one-year Phase III efficacy data and accompanied by programs to support patient access.
Help us improve.
